I-03 Sulav Duwal
Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1
Wednesday 10:20-11:40 |
I-04 Lisa Ehmann
Pharmacokinetics of meropenem in critically ill patients with varying renal function
Wednesday 10:20-11:40 |
I-10 Natalie Filmann
Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation
Wednesday 10:20-11:40 |
I-19 Andy Gewitz
PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration
Wednesday 10:20-11:40 |
I-41 Christoph Hethey
Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays
Wednesday 10:20-11:40 |
I-43 Eef Hoeben
Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir
Wednesday 10:20-11:40 |
I-52 Swati Jaiswal
Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters
Wednesday 10:20-11:40 |
I-62 Anke Kip
Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients
Wednesday 10:20-11:40 |
I-70 Laure Lalande
Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid
Wednesday 10:20-11:40 |
II-06 Ali Mohamed Ali
Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations
Wednesday 15:10-16:30 |
II-11 Manel Aouri
Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals
Wednesday 15:10-16:30 |
II-16 Catalina Barceló
Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals
Wednesday 15:10-16:30 |
II-18 Ana Bastos
Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients
Wednesday 15:10-16:30 |
II-24 Dimitra Bon
PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model.
Wednesday 15:10-16:30 |
II-30 Margreke Brill
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
Wednesday 15:10-16:30 |
II-34 Charles Burdet
Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers
Wednesday 15:10-16:30 |
II-44 Chunli Chen
Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model
Wednesday 15:10-16:30 |
II-50 Oskar Clewe
Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model
Wednesday 15:10-16:30 |
II-66 Amelia Deitchman
Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves
Wednesday 15:10-16:30 |
II-69 Paolo Denti
Population Pharmacokinetics of Levofloxacin in South African children.
Wednesday 15:10-16:30 |
II-72 Thomas Dorlo
Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model
Wednesday 15:10-16:30 |
III-05 Jesmin Lohy Das
Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar
Thursday 10:05-11:30 |
III-10 Vincent Madelain
Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses
Thursday 10:05-11:30 |
III-15 Ben Margetts
Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population
Thursday 10:05-11:30 |
III-17 Lisa Martial
Population PK model and pharmacokinetic target attainment of micafungin in ICU patients
Thursday 10:05-11:30 |
III-38 Per Olsson Gisleskog
Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes
Thursday 10:05-11:30 |
III-49 Carlos Perez-Ruixo
Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance
Thursday 10:05-11:30 |
III-54 Kimba Eddy Phongi
Population Pharmacokinetics of the Novel Antimalarial OZ439
Thursday 10:05-11:30 |
III-62 Rachel Rose
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.
Thursday 10:05-11:30 |
III-67 Sophie Rhodes
Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study
Thursday 10:05-11:30 |
III-70 Clémence Rigaux
Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients
Thursday 10:05-11:30 |
IV-13 Amaia Soraluce
Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment
Thursday 14:40-16:00 |
IV-17 M. Elena Suarez Gonzalez
How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis
Thursday 14:40-16:00 |
IV-19 Robin Svensson
Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin
Thursday 14:40-16:00 |
IV-28 Anders Thorsted
Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6
Thursday 14:40-16:00 |
IV-32 Bruna Gaelzer Silva Torres
Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats
Thursday 14:40-16:00 |
IV-40 Muhammad Usman
Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function
Thursday 14:40-16:00 |
IV-50 Max von Kleist
Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection
Thursday 14:40-16:00 |
IV-61 Rixt Wijma
Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers
Thursday 14:40-16:00 |
IV-75 Chenguang Zhou
Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey
Thursday 14:40-16:00 |
